FIELD: chemistry.
SUBSTANCE: invention relates to 16α,17α-cyclohexa-17β-(2′-hydroxyethyl)13β-methylgona-1,3,5(10)-trien-3-ol (I) of formula (I), having properties of oestrogen and NF-kB transcription factor inhibitor and cytotoxic activity, and production method thereof.
EFFECT: compound I may be used in medicine for developing anticancer drugs.
4 cl, 1 tbl, 2 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOUNDS, SET, ANDROGENIC COMPOSITION | 2000 |
|
RU2242479C2 |
| 15,15-DIALKYLSTEROID COMPOUNDS AND METHOD OF PREPARATION THEREOF | 1994 |
|
RU2147306C1 |
| BRIDGE-CONTAINING ESTRATRIENES | 1990 |
|
RU2087479C1 |
| 7β-METHYL-3,17αβ-DISULFAMOYLOXY-D-HOMO-6-OXA-ESTRA-1,3,5(10), 8,14-PENTAEN AS BREAST CANCER MCF-7 CELLS GROWTH INHIBITOR | 2016 |
|
RU2619457C1 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING DERIVATIVES OF ESTRA-1,3,5(10)-TRIENE | 1995 |
|
RU2179442C2 |
| DERIVATIVES OF ESTRA-1,3,5(10)-TRIENE, METHOD OF THEIR SYNTHESIS, PHARMACEUTICAL COMPOSITION | 1995 |
|
RU2139885C1 |
| INDUSTRIAL METHOD FOR PRODUCTION OF HIGH PURITY ESTETROL | 2020 |
|
RU2802820C2 |
| SULFAMATE DERIVATIVES, METHOD OF PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITIONS | 1996 |
|
RU2159774C2 |
| 15β-SUBSTITUTED STEROIDS WITH SELECTIVE OESTROGENIC ACTIVITY | 2005 |
|
RU2386637C2 |
| STEROID COMPOUNDS, METHOD FOR SELECTIVE MODIFICATION, PHARMACEUTICAL COMPOSITION | 2001 |
|
RU2255090C2 |
